Search
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Ardeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnNormiflo was withdrawn from the US market in March 2000. … Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500.
Nadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and … Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.
Dezocine
go.drugbank.com/drugs/DB01209ApprovedInvestigationalDezocine is a partial opiate drug and is used for pain management. … Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalAzelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. … It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear.
Mixtures: Vp-zel, Tri-ZelSynonyms: n-nonanedioic acidEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigationalTovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. … [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation.
Synonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamideMenadione
go.drugbank.com/drugs/DB00170ApprovedNutraceuticalA synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Products: VI-PLEX K 10 MG 3 AMPUL, VI-PLEX K 10 MG/2 ML AMPUL, 5 ADETD2C7 immunotoxin
go.drugbank.com/drugs/DB17540InvestigationalD2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL. … D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Synonyms: D2C7-IT